复宏汉霖早盘股价上涨6.09%,现报33.95港元,成交额3866.51万港元。复宏汉霖近日举行2025全球研发日。公司在会上表示,2024年业绩期内,公司在全球范围内完成25项上市注册申请递交,并获得17项批准。截至目前,复宏汉霖已有6款产品在中国获批上市,4款产品在国际获批上市,触达50多个国家和地区。未来四年,复宏汉霖计划在美国再推动8款生物药上市,覆盖帕妥珠单抗、地舒单抗等多个产品。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.